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ABSTRACT 
 
Background/Aims:The rarity of metastatic malignancy in injured liver has been noticed. This 
meta-analysis evaluates the difference in occurrence of metastatic colorectal cancer in healthy 
and chronically injured liver. 
Methodology: Literature search of occurrence of metastatic colorectal cancer in chronically 
injured liver opposed to healthy liver was conducted. Chronically injured/damaged liver 
included cirrhosis, steatosis or fatty liver and infection with Hepatitis virus B or C. 
Results: A total of 7 retrospective studies between 1992 and 2010 matched the selection 
criteria with total of 4049 patients. Results suggest significantly lower incidence of colorectal 
metastasis in chronically injured liver (Pooled odds ratio = 0,260007 (95% CI = 0,176092 to 
0,38391); Chi² (test odds ratio differs from 1) = 45,898818  (df = 1)  P < 0,0001). 
Conclusions: Patients with chronic liver injury have significantly lower occurrence of hepatic 
metastasis of primary colorectal cancer than the patients with healthy liver. 
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INTRODUCTION 
 
The data show that in up to 30% of patients with colorectal cancer, liver metastases 
were observed during first laparotomy (1-4). Also, the most common indication for non 
curative surgery is liver metastases. Thus, liver metastases are the most relevant prognostic 
factor for patients with colorectal carcinoma (5). On the other hand, there are indices that 
chronic liver injury, such as cirrhosis, steatosis and hepatitis B or C infection, could reduce 
the incidence of hepatic metastases of primary colorectal cancer.  
The rarity of the occurrence of metastatic malignancy in injured liver has been noticed 
and described by several authors for almost seventy years (5-9). In 1942, Lisa et al. suggested 
that the cirrhotic liver is not a favorable soil for metastatic tumor cells (7). Since then there 
have been many theories about this phenomenon but the exact reason is still unknown.  
During last twenty years only few articles have been published about colorectal 
metastases to injured liver and there is no meta-analysis or systematic review on the subject. 
We collected all relevant articles and performed a meta-analysis. This meta-analysis evaluates 
the difference in occurrence of metastatic colorectal cancer in healthy and chronically injured 
liver. 
 
 
METHODOLOGY 
 
Searching, selection and data abstraction 
Two independent reviewers (G.A. and B.T.) conducted a comprehensive literature 
search by using predetermined collections of pro formas. All non-English articles were 
translated in English and than analyzed.  Data sources were Ovid, Medline, Embase, 
Cochrane library and Google Scholar. Inclusion criteria were all retrospective analyses 
assessing occurrence of metastatic colorectal cancer in chronically injured liver opposed to 
healthy liver. Chronically injured/damaged liver included cirrhosis, steatosis or fatty liver and 
infection with Hepatitis virus B or C. All this factors was clinically diagnosed according to 
the results of serum chemistry, serology and hepatic imaging (ultrasonography, MR).  
Exclusion criteria were trials with no control group, patients with hepatocellular carcinoma 
and retrospective analyses of patients that underwent chemotherapy. Measured outcome was 
occurrence of metastatic malignancy in injured and in healthy liver. 
All studies are level of evidence 2b (10). Acquired studies with usable data are Hayashi S et 
al. (5), Uetsuji S et al. (8), Song E et al. (11), Utsunomiya T et al. (12), Iascone C et al. (13, 
14), and Qian HG et al (15). Two  studies that had to be excluded are Gervaz P et al. (no 
control group) (16) and Utsunomiya T et al. (not adequate data) (9).  
 
Data synthesis and statistics 
Meta-analysis was preformed using the software MedCalc (version 8.2.0.2). The effect 
sizes as odds ratio (OR) with 95% confidence interval (CI) were calculated. Both random-
effects model and fixed-effect model were used, but interpretation was based on level of 
heterogeneity of the studies. In fixed-effect model, it is assumed that there is no heterogeneity 
in treatment effect between studies, whereas in random-effect model it is assumed that there is 
variation between studies and calculated odds ratio will be more conservative (17).
  
Funnel plot were assessed to provide a visual assessment of whether estimates were 
associated with study size and to detect publication biases. Bias was assessed visually by 
inspection of a bias assessment plot (Fig. 1) and statistically by use of the Horbold-Egger test 
(bias = 0,557891 (92,5% CI = -2,486627 to 3,60241)  P = 0,6838). 
 
 RESULTS 
 
Review of the data extraction showed 100% agreement between the 2 reviewers. A 
total of 7 retrospective studies published between 1992 and 2010 matched the selection 
criteria. Two studies by the same author overlapped so the data from both were merged. Study 
selection process is shown in Figure 2. The results of studies are shown in Table 1. The 
studies assessed combined a total of 4049 patients. Fig. 3 is Forest plot that compares 
incidence of colorectal metastasis in chronically injured liver to incidence of colorectal 
metastasis in liver with no signs of injury. Since there was variations between studies random-
effect model was used for interpretation of the data. Results suggest significantly lower 
incidence of colorectal metastasis in chronically injured liver (Pooled odds ratio = 0,260007 
(95% CI = 0,176092 to 0,38391); Chi² (test odds ratio differs from 1) = 45,898818  (df = 1)  P 
< 0,0001).  
By this we infer with 95% confidence, assuming a random effects model, that the true size of 
the difference between incidence rates was somewhere between 0,17 and 0.38 for the 
chronically injured liver group compared with the control group; that is statistically 
significant, P<0,0001. Also, we can say with 95% confidence, assuming a random effects 
model that for those with chronically injured the true population risk of metastasis is at most 
0.38 of the risk of those with healthy liver. Assuming a fixed effects model a stronger 
inference could be made about a relative risk of 0.32 (the upper confidence limit) but the high 
inter-study variation makes the fixed effects model less appropriate. 
Results are comprehensively shown in Fig. 4.  
 
 
DISCUSSION 
 
Many decades ago it was noted on autopsy studies that patients with chronic liver 
injury had significantly lower incidence of hepatic metastases of different kinds of primary 
malignant tumors (18-20). Since rarity of the occurrence of metastatic disease of colorectal 
cancer origin in injured liver has been noticed and described by number of observers for 
almost seventy years it was our intention to analyze the results of all relevant studies 
published on the subject. This meta-analysis aimed to determine whether chronic liver injury, 
such as cirrhosis, steatosis and hepatitis B or C infection reduces incidence of hepatic 
metastasis of primary colorectal cancer.  
All studies included in meta-analysis are level of evidence 2b (10). Accordingly, this 
meta-analysis is 2a level of evidence. Since there are only a few studies on this subject and it 
is impossible to conduct prospective study, level of evidence 2b is the highest possible.  
This meta-analysis suggests that patients with chronic liver injury have significantly 
lower incidence of hepatic metastasis of colorectal cancer origin. The reason for this 
observation is still unknown. There are several theories and explanations. Lisa et al. suggested 
that cirrhotic liver is not favorable soil for transplanted tumor cells and the rarity of metastatic 
disease to the liver (7). The authors found only 5 case reports and described 6 patients of their 
own but not a single patient had primary colorectal cancer. Lieber et al. offered explanation 
that the fibrosis and subsequent distortion of small vessels in the liver constitute a mechanical 
impediment to the spread of cancerous tissue (6). Certain authors claim that activated immune 
cells residing in livers are effective in killing metastatic tumor cells. Others claim that patients 
with significant chronic liver injury, especially cirrhosis and primary malignant tumors have 
shorter life span thus lower possibility to develop metastases of any primary malignant tumor 
(21).  
High metalloproteinase inhibitor contents and especially altered lectins or lectin 
binding sites in cirrhosis of the liver may help to explain the rare event “metastasis in 
cirrhosis” (22). Pathophysiological pathway of cirrhosis undergoes through the process of 
extracellular matrix remodeling leading to new collagen formation and deposition. The major 
role in matrix degradation is played by matrix metalloproteinases (MMPs), and their tissue 
inhibitors (TIMPs) (23). In progressive liver fibrosis, the overall MMP activity decreases, due 
to increased expression of TIMPs and other anti-proteases expressed by hepatic stellate cells 
and hepatocytes (24). Since fibrosis is the most significant pathological consequence of liver 
injury in fatty liver, process of extracellular matrix remodeling is also present in liver tissue. 
Process of remodeling is practically the same and it is done by MMPs and their TIMPs. 
Chronic hepatitis is accompanied with liver fibrosis and elevation of MMPs and TIMPs. 
Analysis of level of serum matrix metalloproteinase-9 and tissue inhibitor of 
metalloproteinase-1 in chronic hepatitis C patients showed statistically significant increase of 
MMP-9 and TIMP-1 in hepatitis C patients compared with control group. Also there was a 
positive correlation between TIMP-1 and the degree of fibrosis (25). In progression of 
colorectal cancer MMPs also have great role. Namely, the balance between MMPs and their 
physiological tissue inhibitors (TIMPs) is crucial in tumor invasion and progression (26). Is 
seems that increased activity of MMPs stimulates tumor growth. Experimental use of 
selective MMP inhibitor resulted in a dose-dependent delay in the growth of tumors and 
reduced volume by 75% when treatment was begun 5 days after implantation (27). Due to 
these findings it is possible that increased expression of TIMPs have inhibitory role in the 
process of colonization and formation of colorectal metastasis in chronically injured liver. 
Another possible proposed mechanism could lie in galectin-3. Galectin-3, member of the β-
galactoside-binding proteins, is an intracellular and extracellular lectin which interacts with 
intracellular glycoproteins, cell surface molecules and extracellular matrix proteins. Galectin-
3 is expressed widely in epithelial and immune cells and its expression is correlated with 
cancer aggressiveness and metastasis (28). When Galectin-3 is blocked with carbohydrate-
based galectin-3 inhibitors, metastasis-associated tumor cell adhesion could be inhibited 
efficiently (29). On the other hand, Galectin-3 is expressed in various tissues and organs but is 
significantly absent in normal hepatocytes. In chronic liver injuri such as cirrhosis and 
hepatitis C induces fibrosis expresion of Galectin-3 and Galectin-3-binding protein was 
increased (30, 31). This could lead to conclusion that liver Galectin-3 receptors are being 
occupied thus not allowing metastatic tumor cell to adhere.  
Yet another possible mechanism could lie in chemokines. It is said that chemokine 
involvement in cancer development and progression is divergent: while speciﬁc chemokines 
promote, others can inhibit such processes (32). On the other hand chemokines and their 
receptors are marked as key players i pathophysiology of hepatitis and cirrhosis (33, 34). Here 
could lay yet not fully explained mechanism of lower incidence of hepatic metastases of 
colorectal cancer. 
 
 
CONCLUSIONS 
 
Colorectal cancer is a major health problem and hepatic metastases of colorectal 
cancer deteriorate prognosis. Rarity of the occurrence of metastatic disease of primary 
colorectal cancer in injured liver has been noticed and described for almost seventy years but 
was not so often explored and never completely explained. This meta-analysis proved that 
patients with chronic liver injury have significantly lower occurrence of hepatic metastasis of 
primary colorectal cancer than the patients with healthy liver and we reviewed possible 
theories for this observation. Studies included did not analyze if lower occurrence affect 
survival rate and also all studies do not distinguish different stages of liver injury. Previously, 
six independent determinants of survival in patients without intervention (natural history) 
were identified in the following order: percentage liver volume replaced by tumour,  grade of 
malignancy of the primary tumour, presence of extrahepatic disease, mesenteric lymph-node 
involvement, serum carcino-embryonic antigen, and age (35). Observations and conclusion of 
this meta-analysis opens possibilities for exploration of how to induce or amplify mechanisms 
for elimination of metastatic cells that come in contact with the liver thus improving 
prognosis of patients with colorectal cancer without liver metastases. 
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Figure legends 
 
 
 
FIGURE 1 Bias assessment plot. 
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FIGURE 2 Flow diagram of retrospective analysis with adequate data (see text for details). 
 
 
Potentially relevant retrospective analysis identified for retrieval:  
Colorectal liver metastasis + fatty liver                                    2 
Colorectal liver metastasis + hepatitis B or C infection            4 
 Colorectal liver metastasis + cirrhosis                                       3 
 
Excluded: 2 
Gervaz P et al (no control group) 
Utsunomiya T (not adequate data) 
 
Potentially appropriate to be included in the metaanalysis:  
n=7 
 
 
 
 
Data from two article of the same author 
merged in one because of overlap 
( Iascone et al)  
 
 
 
 
Retrospective analysis with usable data: n=6 
Song E et al. 
Utsunomiya T et al.  
Uetsuji S et al.  
Hayashi S et al. 
Iascone C et al.  
Qian HG et al 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3 Forest plot that compares incidence of colorectal metastasis in chronically injured 
liver to incidence of colorectal metastasis in liver with no signs of injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds ratio meta-analysis plot [random effects]
0,01 0,1 0,2 0,5 1 2
Hayashi, Masuda et al. 1997 0,09 (0,01, 0,33)
Iascone, Ruperto et al. 2005 0,23 (0,14, 0,35)
Qian, Zhang et al. 2010 0,31 (0,14, 0,60)
Song, Chen et al. 2001 0,42 (0,19, 0,86)
Uetsuji, Yamamura et al. 1992 0,04 (0,00, 0,36)
Utsunomiya, Saitsu et al. 1999 0,33 (0,06, 1,08)
combined [random] 0,26 (0,18, 0,38)
odds ratio (95% confidence interval)
FIGURE 4 Results of the meta-analysis. 
 
 
 
Odds ratio meta-analysis   
 
Stratum Table (xt, xc, nt, nc) 
1 3 85 34 316 Utsunomiya, Saitsu et al. 1999 
2 0 40 46 164 Uetsuji, Yamamura et al. 1992 
3 10 119 64 319 Song, Chen et al. 2001 
4 10 254 104 808 Qian, Zhang et al. 2010 
5 28 174 263 369 Iascone, Ruperto et al. 2005 
6 2 115 119 603 Hayashi, Masuda et al. 1997 
 
Stratum Odds ratio 95% CI (CML) % Weights (fixed, random) 
1 0,328028 0,063065 1,084864 5,382285 9,095765 Utsunomiya, Saitsu et al. 1999 
2 0,043674 0 0,363354 6,096076 1,8743 Uetsuji, Yamamura et al. 1992  
3 0,418855 0,185775 0,857467 12,133887 21,47105 Song, Chen et al. 2001 
4 0,305875 0,140421 0,597477 18,323258 23,017847 Qian, Zhang et al. 2010 
5 0,225777 0,141563 0,35054 44,759159 37,67424 Iascone, Ruperto et al. 2005 
6 0,088126 0,010419 0,334457 13,305335 6,866798 Hayashi, Masuda et al. 1997 
 
Fixed effects (Mantel-Haenszel, Robins-Breslow-Greenland) 
Pooled odds ratio = 0,239969 (95% CI = 0,177679 to 0,324097) 
Chi² (test odds ratio differs from 1) = 97,781758  P < 0,0001 
 
 
Random effects (DerSimonian-Laird) 
Pooled odds ratio = 0,260007 (95% CI = 0,176092 to 0,38391) 
Chi² (test odds ratio differs from 1) = 45,898818  (df = 1)  P < 0,0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1 The results of included studies with results of each study separately with number of 
patients 
 
Study Injured liver 
Injured liver with 
metastasis 
Non-injured 
liver 
Non-injured liver 
with metastasis 
Song et.al 74 10 438 119 
Utsomiya et. al 37 3 401 85 
Uetsuji et.al 46 0 204 40 
Hayashi et.al 121 2 718 115 
Iascone et.al 291 28 543 174 
Qian et al. 114 10 1062 254 
Total 683 53 3366 787 
 
